Day of Embryo Transfer for Patients Undergoing In Vitro Fertilization - Full Text View

Sponsored by:	Stanford University
Information provided by:	Stanford University
ClinicalTrials.gov Identifier:	NCT00615771

Purpose

We are examining whether pregnancy rates differ based on day of embryo transfer in patients who replace all available embryos after an IVF cycle. Patients must be undergoing IVF treatment at Stanford University and patients will not receive compensation for their participation (no medical costs covered or patient payment for participation).

Condition	Intervention
Infertility	Procedure: Day of embryo transfer

MedlinePlus related topics: Infertility

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Open Label, Active Control, Single Group Assignment, Efficacy Study
Official Title:	Embryo Transfer on Day 2 vs. Day 3 After Oocyte Retrieval in Patients Who Plan to Replace All Embryos After an In Vitro Fertilization Cycle

Further study details as provided by Stanford University:

Primary Outcome Measures:

Pregnancy rates

Secondary Outcome Measures:

Live birth rates
Multiple gestation rates

Estimated Enrollment:	242
Study Start Date:	January 2007

Detailed Description:

The decision on the number of embryos to transfer after an IVF cycle is based on the number of available embryos, the quality of the embryos, the patient's age, and the goal of limiting multiple gestations. Stanford Fertility Center and most IVF centers examine the embryos on the third day after oocyte (egg) retrieval to select for the best quality embryos to transfer, and depending on quality, the remaining embryos are frozen to be used in the future. Patients with a limited number of embryos, those that plan to replace all available embryos after an IVF cycle, do not need to wait until the third day after oocyte retrieval to select embryos, and may replace the embryos on the second day after the oocyte retrieval. We are examining whether pregnancy rates differ among these patients based on the day of embryo transfer (Day 2 vs. Day3). Patients must be undergoing IVF treatment at Stanford University and patients will not receive compensation for their participation (no medical costs covered or patient payment for participation).

Eligibility

Ages Eligible for Study:	18 Years to 50 Years
Genders Eligible for Study:	Female
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:Patients undergoing fresh IVF cycle at Stanford Fertility Center who plan on replacing all available embryos.
 Exclusion Criteria:Patients that do not meet above criteria.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00615771

Locations

United States, California
Stanford University School of Medicine	Recruiting
Stanford, California, United States, 94305
Contact: Lora K Shahine, M.D. 650-498-7911 lshahine@stanford.edu
Principal Investigator: Lora K Shahine
Sub-Investigator: Ruth Bunker Lathi
Sub-Investigator: Lynn m Westphal
Sub-Investigator: Amin A Milki
Sub-Investigator: Valerie Baker
Sub-Investigator: Barry R Behr

Sponsors and Collaborators

Stanford University

Investigators

Principal Investigator:

Lora K Shahine

Stanford University

More Information

Study ID Numbers:	SU-01312008-991
Study First Received:	February 1, 2008
Last Updated:	October 24, 2008
ClinicalTrials.gov Identifier:	NCT00615771
Health Authority:	USA:Stanford University IRB

Study placed in the following topic categories:

Genital Diseases, Female
Infertility
Genital Diseases, Male

ClinicalTrials.gov processed this record on January 14, 2009